← Eichor
Study identifier: NCT07403097 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of CD19 CAR-T Therapy for Refractory SLE

Condition: Systemic Lupus Erythematosus  ·  Sponsor: Chongqing Precision Biotech Co., Ltd

PhasePhase 1
Planned participants18
Who can joinAll sexes, 5 Years to no upper limit
Healthy volunteersNo

About this study

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaodong Zhao  ·  +8613896187845  ·  zhaoxd530@aliyun.com

Yunfei An  ·  +8618623070626  ·  anyf82@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

Children's Hospital of Chongqing Medical UniversityChongqing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07403097